Cullinan Therapeutics (CGEM) Other Non Operating Income (2020 - 2026)
Cullinan Therapeutics (CGEM) posted quarterly Other Non Operating Income of -$62000.0 for Q1 2026, up 27.06% year-over-year from -$48796.3 in Q1 2025, and up 10.14% quarter-over-quarter from -$69000.0 in Q4 2025.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Other Non Operating Income (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$62000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 27.06% year-over-year to -$62000.0; the TTM figure through Mar 2026 stood at -$420000.0 (down 75.0% YoY), while the FY2025 annual figure was -$443000.0, down 122.61% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$62000.0, up from -$69000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $298000.0 in Q4 2022, with the low at -$241000.0 in Q2 2022.
- The 5-year median for Other Non Operating Income is -$69000.0 (2025), against an average of -$27200.0.
- Peak annual rise in Other Non Operating Income reached 7350.0% in 2022, while the deepest fall reached 2912.5% in 2022.
- Cullinan Therapeutics' Other Non Operating Income stood at $298000.0 in 2022, then sank by 139.26% to -$117000.0 in 2023, then soared by 105.13% to $6000.0 in 2024, then slumped by 1250.0% to -$69000.0 in 2025, then advanced by 10.14% to -$62000.0 in 2026.
- Business Quant data shows CGEM's Other Non Operating Income at -$62000.0 in Q1 2026, -$69000.0 in Q4 2025, and -$108000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -98,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -69,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Jun 30, 2025 | -181,000.00 |
| Mar 31, 2025 | -85,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | -89,000.00 |
| Jun 30, 2024 | -72,000.00 |
| Mar 31, 2024 | -44,000.00 |
| Dec 31, 2023 | -117,000.00 |
| Sep 30, 2023 | 180,000.00 |
| Jun 30, 2023 | 69,000.00 |
| Mar 31, 2023 | 107,000.00 |
| Dec 31, 2022 | 298,000.00 |
| Jun 30, 2022 | -241,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -8,000.00 |
| Mar 31, 2021 | -2,000.00 |